Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2004

View Archived Issues

Perlegen and Pfizer to analyze drug response in patients with major depression

Cypress Bioscience, Forest and Pierre Fabre announce agreement for milnacipran

HemispheRx and Vanderbilt University announce joint SARS clinical program

Metabasis Therapeutics announces collaboration to develop treatments for hepatitis C

Purdue Pharma files petition with FDA for generic forms of OxyContin

Gefitinib shows promise in the treatment of recurrent glioblastoma

Protective effects against UV irradiation reported for topical lycopene

Cell type-specific metabolism of testosterone in human skin

Acumen and Merck team to develop drugs for Alzheimer's disease

AnorMED expands Fosrenol licensing agreement

Boehringer Ingeheim claims new glucocorticoid receptor modulators and their use

Novel NHE-1 inhibitors in early development at Aventis

New HCV NS5B inhibitors identified at NeoGenesis

Chinese researchers design dual 5-HT/NA reuptake inhibitors for use as antidepressants

MediGene names Yamanouchi as pan-European partner for prostate cancer products

Corixa and GSK Bio to commence phase I study of tuberculosis vaccine

Aventis claims new NHE-3 inhibitors for sleep apnea and other disorders

Genzyme presents new kallikrein/urokinase inhibitors for pain, inflammation and cancer

Studies support antiinflammatory and antiatherosclerotic effects of PPARgamma agonist

AVE-7688 reduces nephropathy in type 2 diabetes

Pharmacological profile of 5-HT2C agonist YM-348

Development of an improved orally active 5-lipoxygenase inhibitor

Novel mixed opioid analgesic with limited effects on respiratory function

Roche submits European MAA for MabThera

Eloxatin submitted for adjuvant treatment of colon cancer in U.S. and Europe

New phase II trial of Trovax in colorectal cancer cleared to begin in U.K.

Taxotere approved in Japan for esophageal cancer

HER-2 Protein AutoVac induces antibody responses in breast cancer trial

First world launch of Pfizer's antifungal agent fosfluconazole in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...